Is Alembic a good stock to invest in?

Alembic can be analyzed on the following key metrics - TTM P/E: 11.7 Sector P/E: 18.58 Dividend Yield: 1.92% D/E ratio: -

Alembic Share Price

Sector: Biotechnology & Drugs

Powered by

123.80 -1.40 (-1.12%)

1D
5D
1M
3M
6M
1Y
5Y
MAX

Price Range

Today’s Low 122.65

Today’s High 126

52 Week Low 78.2

52 Week High 169

Key Metrics

Market Cap (In Cr) 3216.45
Beta 1.42
Div. Yield (%) 1.92
P/B 1.47
TTM P/E 11.7
Peg Ratio -1.33
Sector P/E 18.58
D/E 0.01
Open Price 126
Prev Close 125.2

View All Metrics

Alembic Analysis

Price Analysis

1 Week

-8.59%
3 Months

-17.13%
6 Month

18.28%
YTD

38.41%
1 Year

56.09%

Risk Meter

47% Low risk
47% Moderate risk
47% Balanced Risk
47% High risk
47% Extreme risk

Alembic News

Premium

Alembic Pharmaceuticals Q2 Results Live: Profit Rise by 12.33% YOY

1 min read . 08 Nov 2024

Premium

Stocks to Watch: Tech Mahindra, HDFC Bank, Kotak Bank, Jio Financial, and more

3 min read . 21 Oct 2024

The Prime Minister’s internship scheme is open to those in the age group of 21-24 years. (Bachchan Kumar/HT PHOTO)

Premium

Mahindra, Max Life Insurance, Alembic Pharma take lead in PM internship scheme

2 min read . 03 Oct 2024

Stock market today: Nifty 50 index has crucial support is now placed at 25,150 levels, believes Vaishali Parekh of Prabhudas Lilladher. (Photo: Courtesy Prabhudas Lilladher)

Premium

Buy or sell: Vaishali Parekh recommends three stocks to buy today — 4 September

3 min read . 04 Sep 2024

View More News

Alembic Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2024

Total Revenue
157.49

Selling/ General/ Admin Expenses Total
23.03

Depreciation/ Amortization
7.84

Other Operating Expenses Total
28.63

Total Operating Expense
108.46

Operating Income
49.03

Net Income Before Taxes
102.69

Net Income
268.62

Diluted Normalized EPS
10.46

Period
2023

Total Revenue
127.24

Selling/ General/ Admin Expenses Total
40.18

Depreciation/ Amortization
1.73

Other Operating Expenses Total
1.71

Total Operating Expense
104.24

Operating Income
23

Net Income Before Taxes
86.8

Net Income
190.65

Diluted Normalized EPS
7.77

Period
2022

Total Revenue
78.22

Selling/ General/ Admin Expenses Total
37.51

Depreciation/ Amortization
1.78

Other Operating Expenses Total
1.7

Total Operating Expense
68.78

Operating Income
9.44

Net Income Before Taxes
97.86

Net Income
222.06

Diluted Normalized EPS
8.57

Period
2021

Total Revenue
73.52

Selling/ General/ Admin Expenses Total
36.58

Depreciation/ Amortization
1.51

Other Operating Expenses Total
1.58

Total Operating Expense
66.39

Operating Income
7.13

Net Income Before Taxes
17.04

Net Income
342.84

Diluted Normalized EPS
13.34

Period
2020

Total Revenue
73.93

Selling/ General/ Admin Expenses Total
35.41

Depreciation/ Amortization
1.28

Other Operating Expenses Total
1.16

Total Operating Expense
73.87

Operating Income
0.05

Net Income Before Taxes
93.17

Net Income
329.12

Diluted Normalized EPS
12.8

Period
2019

Total Revenue
123.81

Selling/ General/ Admin Expenses Total
32.41

Depreciation/ Amortization
1.36

Other Operating Expenses Total
1.34

Total Operating Expense
108.37

Operating Income
15.44

Net Income Before Taxes
44.67

Net Income
213.1

Diluted Normalized EPS
8.29

Period
2018

Total Revenue
125.3

Selling/ General/ Admin Expenses Total
31.68

Depreciation/ Amortization
3.49

Other Operating Expenses Total
1.58

Total Operating Expense
117.97

Operating Income
7.33

Net Income Before Taxes
44.18

Net Income
162.98

Diluted Normalized EPS
5.99

View detailed financials

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Alembic Technical

Moving Average SMA

5 Day127.7
10 Day131.28
20 Day128.1

50 Day136.85
100 Day139.34
300 Day117.56

Alembic Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Dishman Carbogen Amcis
218.15
-2.4
-1.09
282.95
132.75
3420.22

RPG Life Sciences
2027.1
-16.25
-0.8
2976.7
1290.3
3352.62

Alembic
123.8
-1.4
-1.12
169
78.2
3179.18

Indoco Remedies
299.5
-4.8
-1.58
416.95
286.5
2761.39

Suven Life Sciences
118
-2.8
-2.32
169
75.95
2573.27

Alembic Shareholding

Shareholding Pattern

Shareholding Trend

Shareholding(%) v/s Date

View All

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

08-Nov-24
Quarterly Results & Other

12-Aug-24
Quarterly Results

13-May-24
Audited Results & Final Dividend

14-Feb-24
Quarterly Results

08-Nov-23
Quarterly Results

10-Aug-23
Quarterly Results

12-May-23
Audited Results & Final Dividend

09-Feb-23
Quarterly Results

14-Nov-22
Quarterly Results

10-Aug-22
Quarterly Results

Meeting Date
Announced on
Purpose

12-Aug-24
11-Jul-24
AGM

10-Aug-23
12-May-23
AGM

20-Sept-22
10-Aug-22
AGM

23-May-22
19-Apr-22
POM

06-Aug-21
05-Jul-21
AGM

Announced on
Record Date
Ex-Dividend
Dividend Value

13-May-24
05-Aug-24
05-Aug-24
2.4

12-May-23
03-Aug-23
03-Aug-23
2.2

05-May-22
13-Sept-22
12-Sept-22
1.8

11-May-21
-
29-Jul-21
0.2

View All

Company Profile

ABOUT Alembic

Industry Biotechnology & Drugs
ISIN INE426A01027
BSE Code 506235
NSE Code ALEMBICLTD

Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.

MANAGEMENT

Malika Amin Chief Executive Officer, Managing Director, Director
Rasesh Shah Chief Financial Officer
Keval Thakkar Chief Compliance Officer, Company Secretary

ALEMBIC SUMMARY

Alembic is trading 1.12% lower at Rs 123.80 as compared to its last closing price. Alembic has been trading in the price range of 126 & 122.65. Alembic has given 38.41% in this year & -8.59% in the last 5 days.

Alembic has TTM P/E ratio 11.7 as compared to the sector P/E of 18.58.

The company posted a net profit of 121.03 Crores in its last quarter.

Listed peers of Alembic include Dishman Carbogen Amcis (-1.09%), RPG Life Sciences (-0.8%), Alembic (-1.12%) etc.

Alembic has a 70.88% promoter holding & 29.12% public holding.

FAQs about Alembic

Alembic is trading at 123.80 as on 21 Nov, 2024 3:29:08 PM. This is -1.12% lower as compared to its previous closing price of 125.2

The market capitalization of Alembic is 3216.45 Cr as on 21 Nov, 2024 3:29:08 PM.

The 52 wk high for Alembic is 169 whereas the 52 wk low is 78.2

Alembic can be analyzed on the following key metrics -

TTM P/E: 11.7
Sector P/E: 18.58
Dividend Yield: 1.92%
D/E ratio: -

Alembic reported a net profit of 268.62 Cr in 2024.

Alembic Quick Links

Equity Quick Links

Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks

Alembic Share Price

Price Range

Price Range

Key Metrics

Alembic Analysis

Alembic News

Alembic Pharmaceuticals Q2 Results Live: Profit Rise by 12.33% YOY

Stocks to Watch: Tech Mahindra, HDFC Bank, Kotak Bank, Jio Financial, and more

Mahindra, Max Life Insurance, Alembic Pharma take lead in PM internship scheme

Buy or sell: Vaishali Parekh recommends three stocks to buy today — 4 September

Alembic Financials

Forecast

Forecast

Forecast

Alembic Technical

Alembic Peers

Alembic Shareholding

Shareholding Pattern

Shareholding Trend

Corporate Actions

Company Profile

ABOUT Alembic

MANAGEMENT

ALEMBIC SUMMARY

FAQs about Alembic

Wait for it…

Wait for it…

Congratulations!

Subscribe to continue